MarketPeel
Insider Trading Intelligence
Pricing
…
HC

Helen Louise Collins

KURA
DIRECTOR · KURA ONCOLOGY, INC. · CIK 0001701247
FILING MIX · LIFETIME50%/50%
BUYS
26
SELLS
26
TOTAL VALUE
$5.52M
COMPANIES
3
ACTIVE SINCE
Jul 2021
HOLDINGS NOW
96,277
AVG SELL PX
$30.79
TRADE KIND
SHOWING 52 / 52
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
10 backtested trades · 8 horizons · 28 pending
Forward-return performance of every backtestable P/S trade by Helen Louise Collins, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d10+70.00%-3.97%-0.74%-3.23%-6.83%—
14d10+50.00%+0.43%-0.81%+1.24%+2.07%—
30d10+50.00%+14.53%+2.47%+12.05%+6.83%—
60d10+50.00%+19.13%+6.44%+12.93%-8.62%—
90d10(3 pending)+28.57%+22.66%+8.64%+14.02%+8.03%—
180d10(8 pending)+50.00%-13.50%+0.92%-14.42%-14.42%—
1y10(8 pending)+100.00%-28.43%+9.38%-37.81%-37.81%—
2y10(9 pending)+0.00%+90.26%+32.84%+57.42%+57.42%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
KURA · 35,000 shares · as of Jun 4, 2026
011,50023,00034,50046,00020222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 26 buys / 26 sellsCOVERAGE · 20 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,599$43.87$114.0K26,133Jun 17, 2026Jun 22, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,133$44.74$50.7K25,000Jun 17, 2026Jun 22, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
PURCHASE
CHIEF MEDICAL OFFICER
5,000$2.48$12.4K30,000Jun 17, 2026Jun 22, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE
CHIEF MEDICAL OFFICER
5,000——121,268Jun 17, 2026Jun 22, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,268$42.83$54.3K28,732Jun 17, 2026Jun 22, 2026 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
35,000——35,000Jun 4, 2026Jun 4, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
PURCHASE
CHIEF MEDICAL OFFICER
5,000$2.48$12.4K30,000May 18, 2026May 20, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
223$41.21$9.2K25,000May 18, 2026May 20, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,475$39.53$137.4K26,525May 18, 2026May 20, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,302$40.25$52.4K25,223May 18, 2026May 20, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE
CHIEF MEDICAL OFFICER
5,000——126,268May 18, 2026May 20, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
140$45.81$6.4K29,860Apr 17, 2026Apr 21, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE
CHIEF MEDICAL OFFICER
5,000——131,268Apr 17, 2026Apr 21, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,441$48.06$117.3K25,000Apr 17, 2026Apr 21, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
PURCHASE
CHIEF MEDICAL OFFICER
5,000$2.48$12.4K30,000Apr 17, 2026Apr 21, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,419$47.39$114.6K27,441Apr 17, 2026Apr 21, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
PURCHASE
CHIEF MEDICAL OFFICER
40,000$2.48$99.2K65,000Mar 25, 2026Mar 27, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
40,000$35.10$1.40M25,000Mar 25, 2026Mar 27, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE
CHIEF MEDICAL OFFICER
40,000——136,268Mar 25, 2026Mar 27, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
PURCHASE
CHIEF MEDICAL OFFICER
5,000$2.48$12.4K30,000Mar 17, 2026Mar 19, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,000$27.76$138.8K25,000Mar 17, 2026Mar 19, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE
CHIEF MEDICAL OFFICER
5,000——176,268Mar 17, 2026Mar 19, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
PURCHASE
CHIEF MEDICAL OFFICER
10,129$2.48$25.1K35,129Mar 10, 2026Mar 11, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE
CHIEF MEDICAL OFFICER
10,129——181,268Mar 10, 2026Mar 11, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
10,129$30.19$305.8K25,000Mar 10, 2026Mar 11, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
PURCHASE
CHIEF MEDICAL OFFICER
29,871$2.48$74.1K54,871Mar 9, 2026Mar 11, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE
CHIEF MEDICAL OFFICER
29,871——191,397Mar 9, 2026Mar 11, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
29,871$30.02$896.8K25,000Mar 9, 2026Mar 11, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE
CHIEF MEDICAL OFFICER
45,000——221,268Feb 17, 2026Feb 19, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
PURCHASE
CHIEF MEDICAL OFFICER
45,000$2.48$111.6K70,000Feb 17, 2026Feb 19, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
45,000$26.17$1.18M25,000Feb 17, 2026Feb 19, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
150,000——150,000Feb 12, 2026Feb 17, 2026 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——25,000Feb 12, 2026Feb 17, 2026 ↗View →
IOBT
IO BIOTECH, INC.
PURCHASEGRANT
Stock grant
35,144——35,144Jun 5, 2025Jun 6, 2025 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
28,500——28,500Jun 5, 2025Jun 6, 2025 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
171,000——171,000Feb 6, 2025Feb 10, 2025 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE
CHIEF MEDICAL OFFICER
816——266,268Oct 18, 2024Oct 22, 2024 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
PURCHASE
CHIEF MEDICAL OFFICER
816$2.48$2.0K816Oct 18, 2024Oct 22, 2024 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
816$30.00$24.5K0Oct 18, 2024Oct 22, 2024 ↗View →
IOBT
IO BIOTECH, INC.
PURCHASEGRANT
Stock grant
45,642——45,642Jun 6, 2024Jun 7, 2024 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
26,000——26,000Jun 5, 2024Jun 7, 2024 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
20,000$25.07$501.5K0Apr 11, 2024Apr 15, 2024 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
PURCHASE
CHIEF MEDICAL OFFICER
20,000$2.48$49.6K20,000Apr 11, 2024Apr 15, 2024 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
SALE
CHIEF MEDICAL OFFICER
20,000——267,084Apr 11, 2024Apr 15, 2024 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
185,000——185,000Feb 13, 2024Feb 15, 2024 ↗View →
IOBT
IO BIOTECH, INC.
PURCHASEGRANT
Stock grant
64,238——64,238Nov 15, 2023Nov 17, 2023 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
26,000——26,000May 31, 2023Jun 2, 2023 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
206,000——206,000Apr 4, 2023Apr 6, 2023 ↗View →
ELVN
ENLIVEN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
287,084——287,084Feb 23, 2023Feb 27, 2023 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
23,000——23,000Jun 21, 2022Jun 23, 2022 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
46,000——46,000Jul 28, 2021Jul 29, 2021 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
19,166——19,166Jul 28, 2021Jul 29, 2021 ↗View →
Other insiders · KURA
Loading peer insiders…
About this filer
CIK 0001701247
ROLE
Director
PRIMARY
KURA
COMPANIES
3
ACTIVE SINCE
Jul 2021
MARKETPEEL · /INSIDER/0001701247DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback